Literature DB >> 25242395

Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator.

Sonja Grill1, Mahdi Fallah2, Robin J Leach3, Ian M Thompson4, Stephen Freedland2, Kari Hemminki5, Donna P Ankerst6.   

Abstract

PURPOSE: A detailed family history provides an inexpensive alternative to genetic profiling for individual risk assessment. We updated the PCPT Risk Calculator to include detailed family histories.
MATERIALS AND METHODS: The study included 55,168 prostate cancer cases and 638,218 controls from the Swedish Family Cancer Database who were 55 years old or older in 1999 and had at least 1 male first-degree relative 40 years old or older and 1 female first-degree relative 30 years old or older. Likelihood ratios, calculated as the ratio of risk of observing a specific family history pattern in a prostate cancer case compared to a control, were used to update the PCPT Risk Calculator.
RESULTS: Having at least 1 relative with prostate cancer increased the risk of prostate cancer. The likelihood ratio was 1.63 for 1 first-degree relative 60 years old or older at diagnosis (10.1% of cancer cases vs 6.2% of controls), 2.47 if the relative was younger than 60 years (1.5% vs 0.6%), 3.46 for 2 or more relatives 60 years old or older (1.2% vs 0.3%) and 5.68 for 2 or more relatives younger than 60 years (0.05% vs 0.009%). Among men with no diagnosed first-degree relatives the likelihood ratio was 1.09 for 1 or more second-degree relatives diagnosed with prostate cancer (12.7% vs 11.7%). Additional first-degree relatives with breast cancer, or first-degree or second-degree relatives with prostate cancer compounded these risks.
CONCLUSIONS: A detailed family history is an independent predictor of prostate cancer compared to commonly used risk factors. It should be incorporated into decision making for biopsy. Compared with other costly biomarkers it is inexpensive and universally available.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biopsy; breast neoplasms; family; likelihood functions; prostatic neoplasms

Mesh:

Year:  2014        PMID: 25242395      PMCID: PMC5034721          DOI: 10.1016/j.juro.2014.09.018

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

1.  Performance of common genetic variants in breast-cancer risk models.

Authors:  Sholom Wacholder; Patricia Hartge; Ross Prentice; Montserrat Garcia-Closas; Heather Spencer Feigelson; W Ryan Diver; Michael J Thun; David G Cox; Susan E Hankinson; Peter Kraft; Bernard Rosner; Christine D Berg; Louise A Brinton; Jolanta Lissowska; Mark E Sherman; Rowan Chlebowski; Charles Kooperberg; Rebecca D Jackson; Dennis W Buckman; Peter Hui; Ruth Pfeiffer; Kevin B Jacobs; Gilles D Thomas; Robert N Hoover; Mitchell H Gail; Stephen J Chanock; David J Hunter
Journal:  N Engl J Med       Date:  2010-03-18       Impact factor: 91.245

2.  Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.

Authors:  Pietro Pepe; Francesco Aragona
Journal:  Can J Urol       Date:  2013-02       Impact factor: 1.344

3.  Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.

Authors:  Donna P Ankerst; Josef Hoefler; Sebastian Bock; Phyllis J Goodman; Andrew Vickers; Javier Hernandez; Lori J Sokoll; Martin G Sanda; John T Wei; Robin J Leach; Ian M Thompson
Journal:  Urology       Date:  2014-06       Impact factor: 2.649

4.  Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators.

Authors:  Robert K Nam; Michael W Kattan; Joseph L Chin; John Trachtenberg; Rajiv Singal; Ricardo Rendon; Laurence H Klotz; Linda Sugar; Christopher Sherman; Jonathan Izawa; David Bell; Aleksandra Stanimirovic; Vasundara Venkateswaran; Eleftherios P Diamandis; Changhong Yu; D Andrew Loblaw; Steven A Narod
Journal:  J Clin Oncol       Date:  2011-06-20       Impact factor: 44.544

5.  Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.

Authors:  Greg Trottier; Monique J Roobol; Nathan Lawrentschuk; Peter J Boström; Kimberly A Fernandes; Antonio Finelli; Karen Chadwick; Andrew Evans; Theodorus H van der Kwast; Ants Toi; Alexandre R Zlotta; Neil E Fleshner
Journal:  BJU Int       Date:  2011-04-20       Impact factor: 5.588

6.  External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population.

Authors:  Dipen J Parekh; Donna Pauler Ankerst; Betsy A Higgins; Javier Hernandez; Edith Canby-Hagino; Timothy Brand; Dean A Troyer; Robin J Leach; Ian M Thompson
Journal:  Urology       Date:  2006-12       Impact factor: 2.649

7.  Predicting prostate cancer risk through incorporation of prostate cancer gene 3.

Authors:  Donna Pauler Ankerst; Jack Groskopf; John R Day; Amy Blase; Harry Rittenhouse; Brad H Pollock; Cathy Tangen; Dipen Parekh; Robin J Leach; Ian Thompson
Journal:  J Urol       Date:  2008-08-15       Impact factor: 7.450

8.  The Swedish Family-Cancer Database 2009: prospects for histology-specific and immigrant studies.

Authors:  Kari Hemminki; Jianguang Ji; Andreas Brandt; Seyed Mohsen Mousavi; Jan Sundquist
Journal:  Int J Cancer       Date:  2010-05-15       Impact factor: 7.396

9.  Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: an evaluation of seven common cancers.

Authors:  Ju-Hyun Park; Mitchell H Gail; Mark H Greene; Nilanjan Chatterjee
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

10.  Can Western based online prostate cancer risk calculators be used to predict prostate cancer after prostate biopsy for the Korean population?

Authors:  Dong Hoon Lee; Ha Bum Jung; Jae Won Park; Kyu Hyun Kim; Jongchan Kim; Seung Hwan Lee; Byung Ha Chung
Journal:  Yonsei Med J       Date:  2013-05-01       Impact factor: 2.759

View more
  10 in total

1.  Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.

Authors:  Donna P Ankerst; Martin Goros; Scott A Tomlins; Dattatraya Patil; Ziding Feng; John T Wei; Martin G Sanda; Jonathan Gelfond; Ian M Thompson; Robin J Leach; Michael A Liss
Journal:  Eur Urol Focus       Date:  2018-02-13

2.  Identification of Clinically Significant Prostate Cancer by Combined PCA3 and AMACR mRNA Detection in Urine Samples.

Authors:  Elena S Kotova; Yulia A Savochkina; Yuriy V Doludin; Alexander O Vasilyev; Elena A Prilepskay; Natalia V Potoldykova; Konstantin A Babalyan; Alexandra V Kanygina; Andrey O Morozov; Alexander V Govorov; Dmitry V Enikeev; Elena S Kostryukova; Elena N Ilina; Vadim M Govorun; Dmitry Y Pushkar; Elena I Sharova
Journal:  Res Rep Urol       Date:  2020-09-17

3.  Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort.

Authors:  Matthew B Clements; Emily A Vertosick; Lourdes Guerrios-Rivera; Amanda M De Hoedt; Javier Hernandez; Michael A Liss; Robin J Leach; Stephen J Freedland; Alexander Haese; Francesco Montorsi; Stephen A Boorjian; Cedric Poyet; Donna P Ankerst; Andrew J Vickers
Journal:  Eur Urol       Date:  2021-12-31       Impact factor: 24.267

4.  Integration of magnetic resonance imaging into prostate cancer nomograms.

Authors:  Garrett J Brinkley; Andrew M Fang; Soroush Rais-Bahrami
Journal:  Ther Adv Urol       Date:  2022-05-13

5.  Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy.

Authors:  Mark Thalgott; Martina Kron; Johannes M Brath; Donna P Ankerst; Ian M Thompson; Juergen E Gschwend; Kathleen Herkommer
Journal:  World J Urol       Date:  2017-11-21       Impact factor: 4.226

6.  Family History of Breast or Prostate Cancer and Prostate Cancer Risk.

Authors:  Lauren Barber; Travis Gerke; Sarah C Markt; Samuel F Peisch; Kathryn M Wilson; Thomas Ahearn; Edward Giovannucci; Giovanni Parmigiani; Lorelei A Mucci
Journal:  Clin Cancer Res       Date:  2018-08-06       Impact factor: 12.531

Review 7.  Prostate cancer screening-when to start and how to screen?

Authors:  Kimia Kohestani; Marina Chilov; Sigrid V Carlsson
Journal:  Transl Androl Urol       Date:  2018-02

8.  A risk calculator to inform the need for a prostate biopsy: a rapid access clinic cohort.

Authors:  Amirhossein Jalali; Robert W Foley; Robert M Maweni; Keefe Murphy; Dara J Lundon; Thomas Lynch; Richard Power; Frank O'Brien; Kieran J O'Malley; David J Galvin; Garrett C Durkan; T Brendan Murphy; R William Watson
Journal:  BMC Med Inform Decis Mak       Date:  2020-07-03       Impact factor: 2.796

9.  Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL.

Authors:  Enrique Gomez Gomez; Juan José Salamanca Bustos; Julia Carrasco Valiente; Jose Luis Fernandez Rueda; Ana Blanca; José Valero Rosa; Ines Bravo Arrebola; Javier Marquez López; Juan Manuel Jimenez Vacas; Raul Luque; Maria José Requena Tapia
Journal:  BMJ Open       Date:  2019-11-12       Impact factor: 2.692

Review 10.  Personalized strategies in population screening for prostate cancer.

Authors:  Sebastiaan Remmers; Monique J Roobol
Journal:  Int J Cancer       Date:  2020-06-03       Impact factor: 7.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.